UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo

Cancer cell, 2015-04, Vol.27 (4), p.589-602

2015

Volltextzugriff (PDF)

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

Journal of clinical oncology, 2018-09, Vol.36 (26), p.2684-2692

2018

Volltextzugriff (PDF)

Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia

Blood, 2022-02, Vol.139 (8), p.1135-1146

2022

Volltextzugriff (PDF)

Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance

Hematology, 2009, Vol.2009 (1), p.461-476

2009

Volltextzugriff (PDF)

Pevonedistat (MLN4924), a First‐in‐Class NEDD8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study

British journal of haematology, 2015-05, Vol.169 (4), p.534-543

2015

Volltextzugriff (PDF)

Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia

Critical reviews in oncology/hematology, 2019-09, Vol.141, p.125-138

2019

Volltextzugriff (PDF)

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

The New England journal of medicine, 2012-11, Vol.367 (22), p.2075-2088

2012

Volltextzugriff (PDF)

T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment

International journal of molecular sciences, 2023-07, Vol.24 (15), p.12106

2023

Volltextzugriff (PDF)

CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial

The Lancet. Haematology, 2021-07, Vol.8 (7), p.e481-e491

2021

Volltextzugriff (PDF)

HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs

Nature medicine, 2010-04, Vol.16 (4), p.446-451

2010

Volltextzugriff (PDF)

Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma

Blood, 2014-03, Vol.123 (10), p.1487-1498

2014

Volltextzugriff (PDF)

ERG amplification is a secondary recurrent driver event in myeloid malignancy with complex karyotype and TP53 mutations

Genes chromosomes & cancer, 2022-07, Vol.61 (7), p.399-411

2022

Volltextzugriff (PDF)

Catalyzing improvements in ALL therapy with asparaginase

Blood reviews, 2017-09, Vol.31 (5), p.328-338

2017

Volltextzugriff (PDF)

Tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax and hypomethylating agents with or without dose ramp-up

Leukemia & lymphoma, 2024-02, Vol.65 (2), p.228-234

2024

Volltextzugriff (PDF)

Evaluating the efficacy and toxicity of dose adjusted pegylated L-asparaginase in combination with therapeutic drug monitoring

Annals of hematology, 2023-11, Vol.102 (11), p.3133-3141

2023

Volltextzugriff (PDF)

Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors

American journal of hematology, 2022-03, Vol.97 (3), p.322-328

2022

Volltextzugriff (PDF)

Managing inadequate responses to frontline treatment of chronic myeloid leukemia: A case-based review

Cancer treatment reviews, 2013-05, Vol.39 (3), p.241-251

Bixby, Dale L

2013

Volltextzugriff (PDF)

Risk factors and impact of Clostridium difficile recurrence on haematology patients

Journal of antimicrobial chemotherapy, 2017-05, Vol.72 (5), p.1488-1495

2017

Volltextzugriff (PDF)

Oncology stewardship in acute myeloid leukemia

Annals of hematology, 2022-08, Vol.101 (8), p.1627-1644

2022

Volltextzugriff (PDF)

Impact of number of lumens in central-venous catheters on central-line bloodstream infection (CLABSI) and venous thromboembolism (VTE) risk in patients with acute leukemia

Infection control and hospital epidemiology, 2023-01, Vol.44 (1), p.125-127

2023

Volltextzugriff (PDF)

Real‐world outcomes with immunosuppressive therapy for aplastic anemia in patients treated at the University of Michigan

European journal of haematology, 2024-03, Vol.112 (3), p.424-432

2024

Volltextzugriff (PDF)

Impact of Chemotherapy Educational Videos for Patients with Acute Myeloid Leukemia

Journal of cancer education, 2024-07

2024

Volltextzugriff (PDF)

Cytogenomic array detects a subset of myelodysplastic syndrome with increased risk that is invisible to conventional karyotype

Genes chromosomes & cancer, 2019-11, Vol.58 (11), p.756-774

2019

Volltextzugriff (PDF)

A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia

Haematologica (Roma), 2023-03, Vol.108 (3), p.705-716

2023

Volltextzugriff (PDF)

The leukemia strikes back: a review of pathogenesis and treatment of secondary AML

Annals of hematology, 2019-03, Vol.98 (3), p.541-559

2019

Volltextzugriff (PDF)

1 – 25 von 190

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(178)
Mit Volltextzugriff
(165)

Publikationsform

Sprache

Englisch
(190)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(85)
Science & Technology
(85)
Humans
(66)
Hematology
(50)
Oncology
(48)
Male
(32)
Adult
(30)
Female
(28)
Middle Aged
(27)
Aged
(25)
Leukemia, Myeloid, Acute - Drug Therapy
(19)
Acute Myeloid Leukemia
(17)
Leukemia
(16)
Aged, 80 And Over
(15)
Retrospective Studies
(14)
Young Adult
(14)
Mutation
(12)
Medicine
(11)
Prognosis
(11)
Medicine & Public Health
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia

Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance

Pevonedistat (MLN4924), a First‐in‐Class NEDD8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study

Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment

CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial

HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs

Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma

ERG amplification is a secondary recurrent driver event in myeloid malignancy with complex karyotype and TP53 mutations

Catalyzing improvements in ALL therapy with asparaginase

Tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax and hypomethylating agents with or without dose ramp-up

Evaluating the efficacy and toxicity of dose adjusted pegylated L-asparaginase in combination with therapeutic drug monitoring

Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors

Managing inadequate responses to frontline treatment of chronic myeloid leukemia: A case-based review

Risk factors and impact of Clostridium difficile recurrence on haematology patients

Oncology stewardship in acute myeloid leukemia

Impact of number of lumens in central-venous catheters on central-line bloodstream infection (CLABSI) and venous thromboembolism (VTE) risk in patients with acute leukemia

Real‐world outcomes with immunosuppressive therapy for aplastic anemia in patients treated at the University of Michigan

Impact of Chemotherapy Educational Videos for Patients with Acute Myeloid Leukemia

Cytogenomic array detects a subset of myelodysplastic syndrome with increased risk that is invisible to conventional karyotype

A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia

The leukemia strikes back: a review of pathogenesis and treatment of secondary AML

Suchergebnisse filtern